Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://covid19.nih.gov/

Principal Investigator
Name
Yi Jiang
Degrees
M.D
Institution
Department of General Medicine and Geriatrics ,Chongqing University Central Hospital ,Chongqing Emergency Medical Center, China, 400000
Position Title
M.D
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-694
Initial CDAS Request Approval
Nov 19, 2020
Title
Hormone replacement therapy use and risk of breast cancer incidence and death
Summary
Incidence of breast cancer in the United States has been increasing over the last several decades. Revealing mechanisms for cancer prevention is a significant public health need. The long-term use of hormone replacement therapy (HRT) was associated with increased breast cancer risk. The 2 main hormones used in HRT are oestrogen and progestogen. However, the potential risk of different regimens are unknown. PLCO trial is an ideal cohort to observed long-term different HRT regimens and risk of breast cancer.
Aims

Assessing the risk of breast cancer incidence and death from HRT involving either taking both of these hormones (combined HRT) or just taking oestrogen (oestrogen-only HRT).

Collaborators

None